Comparison of treatment method and Hospital Outcome of Cardiogenic Shock resulting ST-segment Elevation Myocardial Infarction between 2009-2013 and 2014 to 2018 in Shahid Madani Hospital of Tabriz

Abstract

Cardiogenic shock due to decreased cardiac output is defined as a hypoperfusion state of the terminal organs. This shock ranges from mild hypoperfusion to deep shock. In this study, considering the improvement of vascularization and reperfusion methods in the years 2009-2018 and the performance of primary angioplasty with a larger number, it is assumed that the clinical outcome of these patients has improved in the years 2009-2018. Therefore, a study was designed to divide patients in the last decade into two five-year periods, to compare the mortality of the second period with the first period, and also to determine the amount and type of revascularization. Our center is not done, it is necessary to determine the degree of mortality and outcome in this center in order to provide solutions and methods to improve the condition and treatment of these patients if they are higher than the global norms. Materials and Methods: In this cross-sectional descriptive study, by referring to the archive of the Heart Center of Shahid Madani Hospital in Tabriz, the list of all patients who referred to Shahid Madani Hospital of Tabriz University of Medical Sciences during the years 2009 to 2018 with a diagnosis of cardiogenic shock The preparation and records of these patients were reviewed The study checklist then includes demographic criteria (age, sex), risk factors (diabetes, hypertension, hyperlipidemia, smoking, COPD, and renal failure), treatment strategies (CAG, thrombolytic, PCI, CABG, any revascularization or balloon pup) and Hospital mortality was completed. Results: In this study, 450 patients with cardiogenic shock were screened, of which 410 patients had cardiogenic shock with ST-segment elevation. According to the results of this study, the mortality rate in the years 2014-2018 has significantly decreased compared to the years 2009-2013.(P-value:0.01) According to the results obtained, the use of GPIIbIIIa in the years 2014-2018 compared to the years 92-88 There was a significant increase( P-value:0.001), but other treatments were not significantly different